All In MedTech

Device Trial Radar · NCT07649603

Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation

Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation: The PREVENT-AF Study II

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Jun 2027

Primary completion

May 2032

Study completion May 2032

Sponsor

Lead sponsor
University of RochesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pulmonary vein isolation (PVI) via catheter ablation has been successfully employed for years to treat symptomatic atrial fibrillation (AF). Moreover, PVI has not been used as a prophylactic intervention even in groups known to be high-risk for the future development of AF. Preliminary studies, including our pilot PREVENT AF I randomized trial, suggested that prophylactic PVI may be effective at reducing new onset AF and overall AF burden in atrial flutter (AFL) patients. This is a multicenter single-blind randomized controlled trial, "Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation" (PREVENT AF II) to determine if PVI in conjunction with AFL ablation for patients with typical AFL results in a significant reduction in cardiac events and healthcare utilization.

Conditions

  • Atrial Flutter Typical

Interventions

  • Catheter ablationDevice

    CTI ablation; pulmonary vein isolation (PVI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite endpointTime frame: Up to 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.